Biofrontera aims at own drug sales in the field of dermatology, which it expects to start in 2007
Drug Pipeline Compound
BF-Derm1 Clinical Phase II for antihistamine-refractory urticaria
Aminolevulinic acid (ALA) Clinical Phase II for basal cell carcinoma and actinic keratosis
5-HT2B- Antagonist Preclinical development for migraine prophylaxis
Sphingomyelinase Inhibitors Lead compounds
Cysteine Protease Inhibitors Lead optimization
Kinase Inhibitor Lead finding
PAR4 Antagonist Lead finding
PAR2 Antagonist Lead finding
Biofrontera is uniquely positioned among its peers by a combination of natural compound screening, isolation, and chemical derivatization with molecular, cellular and whole animal pharmacology.
Patents
Broad portfolio of patents covering technology, animal models, and novel compounds
Customers
and Partners Advalytix AG, Bayer Cropscience AG, Evotec OAI AG, Janssen Pharmaceutica NV (J&J-Group), Kiadis BV, Merck KGaA, Schering AG, Schwarz Biosciences GmbH, Universities and other research institutions
Executive
Board Prof. Hermann Lübbert, PhD, CEO
Stefan Weber, CFO
Supervisory
Board Prof. Axel Kleemann, PhD (Chairman), Timo Hercegfi (Vice Chairman), Richard Gabriel, Hector J. Gomez, MD, PhD, Ulrich Granzer, MD and Prof. Bernd Wetzel, PhD
Finance Start-up financing of € 10.9 mln in February 1998 (including 2 mln € VC-funds)
In May 2000 Series A round of € 11.6 mln (including 8.7 mln € VC-funds), led by 3i Group
Acquisition of bioleads' assets in 2003, supported and financed by a € 11.6 mln 1st closing of a Series B financing round led by Heidelberg Innovation (including 7.6 mln € VC-funds)
In September 2004 strategic investment by DNAPrint of 20 mln €. Heidelberg Innovation, 3i, TMK and Prof. Dr. Riesner completed the investment to 21.2 mln €.
Investors
DNAPrint genomics Inc., Heidelberg Innovation, 3i, LeVenture, TMK, Prof. Dr. Detlef Riesner, Pricap, TRE, Richard Gabriel, Monica Tamborini, tbg
Team and Premises Staff of 55 on 2000 m2 of fully equipped laboratory space each in Heidelberg and Leverkusen
